Michal Standara

Oncology imaging, prostate mostly. @MOU_Brno @[email protected]

[Dana Drábová #KeepCalmAndCarryOn @DrabovaDana]

Denní hlášení si dávají přestávku. Informace o radiační situaci na Ukrajině a v celé Evropě najdete na @SUJBofficial
Radiační situace na Ukrajině zůstává normální.

[Michal Standara @MStandara]

I leave #ESUR2024 as an “aware competent” and officially ESUR certified Prostate MRI radiologist. Thanks to all of you experts who tirelessly pass on your knowledge to the rest of us.

[Jelle Barentsz @JelleBarentsz]

· For preoperative detection of metastatic lymph nodes in pancreatic and duodenal cancer, USPIO-enhanced MRI showed 83% sensitivity and 92% specificity.

· Nano-particle MRI is promising to detect preoperative MLNs in these types of cancer

https://t.co/ii7JeBaJ1A

[ESUR Junior Network @ESUR_JN]

🚀 Tomorrow's the day! Get ready to dive deep into VI-RADS with Prof. Valeria Panebianco & Dr. Martina Pecoraro. 📅 Join us on May 21st at 18:00 for an enlightening webinar packed with expertise and innovation. Secure your spot now!

[Jelle Barentsz @JelleBarentsz]

Excited to announce the new format of popular 12th ESUR Prostate MRI course June 27-29 in Zeist NL (>250 signed-up already)! Featuring short talks by experts, and full-day of MDT sessions + case-based review + hands-on teaching. Register: https://t.co/ECdDciL9d6

Please Retweet!

[Michal Standara @MStandara]

Great and clear presentation of #PIQUAL 2.0 by @giga_fra today, thanks for simplifying, this will definitely go into a structured report. We'll probably just use Optimal/Acceptable/Inadequate instead of numbers as a result so it doesn't get confusing.

[Imperial Prostate @IP_London]

Headline message from @andreasroder1 - PSA screening trials show a 0.5% absolute risk reduction over ~18-22 years

Is this worth it?

#ipmasterclass24

[Michal Standara @MStandara]

Radiologové, přijďte v sobotu 27.4.2024 na @MOU_Brno MOÚ workshop - MR prostaty pro pokročilé. Probereme PI-RADS, PRECISE, PI-RR a další. Přednášet a diskutovat s vámi budou radiologové, urolog i patolog. Každý bude mít svou diagnostickou stanici. https://t.co/Crm7iL1ixb

[Michal Standara @MStandara]

“Blind deconvolution decreases requirements on temporal resolution of DCE-MRI: Application to 2nd generation pharmacokinetic modeling.”
Next step towards a more robust quantitative #DCE-MRI methodology. https://t.co/sFJaMm0eCX

[Michal Standara @MStandara]

Another wonderful case for our Advanced prostate MRI course at MMCI @MOU_Brno Hint: Read the patient summary.

[David Eldred-Evans @eldredevans]

🚨A new plain English summary of IP1-#Prostagram just published in NIHR evidence

📰Have a read for a nice summary of the multiple publications from trial

🔓Explores how the data was useful in informing design of #Transform trial

https://t.co/TuDp8ex5q7

[Andrew Vickers @VickersBiostats]

TL;DR version: MRI changed how we found prostate cancer, but we didn't update our pathology or treatment guidelines

[ProstateUK Profs @ProstateUKProfs]

Is digital rectal exam (DRE) a good prostate cancer screening test? We know that fear of DRE is one of the biggest barriers to men talking to their GP about prostate concerns. Read our @BJGPjournal paper on why DRE need not be a routine screening test: https://t.co/Rszvi8kiVm

[Michal Standara @MStandara]

It was a great honour to be on the same stage with @vbloegager @CornudF @Mart_Pecoraro and the others. Great session. Thanks.

[Andrea Ponsiglione @A_PonsiglioneMD]

It's time to define optimal PI-RADS cut-off according to population characteristics @ProfPadhani @ESUR_JN @myESR #MRI #ProstateCancer #screening

[Michal Standara @MStandara]

Excellent review on PSA-based screening. However detection still depends on PSA above 3. #Prostagram and other studies show a substantial proportion of cancers in men with PSA 1-3. We need data on these too.

[ProstateUK Profs @ProstateUKProfs]

The @ProstateUK Data and Evidence team led a rapid review with the following key question: Have the benefits and harms of PSA-based #prostatecancer screening changed since the introduction of pre-biopsy MRI and additional testing into the prostate cancer pathway? (1/7)

[Masarykův onkologický ústav Brno @MOU_Brno]

V nové epizodě podcastu Co vy na to, doktore? se věnujeme screeningu rakoviny prostaty. Co se za tímto pojmem skrývá a proč není potřeba se ho obávat? To se dozvíte v rozhovoru s primářem urologického oddělení #MOÚ doc. MUDr. Michalem Staníkem, PhD.
👉https://t.co/Xk6ekIpdAu

[Antti Rannikko @RannikkoAntti]

All studies point to the same direction and are reassuring.
MRI invisible lesions seem less aggressive that MRI visible lesions. We question the value of systematic biopsies in routine prostate cancer diagnostic pathway utilizing MRI. 2/5

[Masarykův onkologický ústav Brno @MOU_Brno]

1/2 V sobotu se konal v posluchárně RECAMO kurz Magnetické rezonance prostaty, na který přijelo 25 radiologů z celé ČR. Ti si vyslechli přednášky od radiologů z #MOÚ MUDr. Křístka, MUDr. Standary a MUDr. Pacala a paní primářky MUDr. Slámové z Nemocnice Nové Město na Moravě.

[Jelle Barentsz @JelleBarentsz]

https://t.co/bVqI7XLMy7
1. Extraprostatic findings (EPFs) are common in prostate MRI
2. EPFs are underreported in 70%
3. 2.4% are clinically relevant